prescribing guide semaglutide tirzepatide Obesity management is evolving. New clinical guidance from the American College of Physicians supports using GLP-1- and GIP-based medications, such as and tirzepatide, as first-line Semaglutide Vs Tirzepatide Weight Loss
Description
Tirzepatide receptor pharmacology and predicted receptor occupancy GIPR-forward dual-incretin design, cAMP-biased GLP-1R with low beta-arrestin, GCGR negative control (EC50 329 nM)

Same dose

Had to take more than the recommended dosage

The medication requires weekly subcutaneous injection and gradual dose escalation to minimize gastrointestinal side effects

The larger individual is receiving roughly half the weight-adjusted dose
